


IN THE CLAIMS

The pending unamended claims are reproduced below.


1-13. (CANCELLED)

14. (PREVIOUSLY PRESENTED) A method of treating dyskinesia in a subject comprising administering to the subject a therapeutically effective amount of a compound of the formula (I):



wherein X is Oxygen or CH<sub>2</sub>;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently Hydrogen, lower alkyl and R<sub>2</sub> and R<sub>3</sub> and/or R<sub>4</sub> and R<sub>5</sub> together may be a group of the formula (II):



wherein R<sub>6</sub> and R<sub>7</sub> are the same or different and are Hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring, wherein the dyskinesia is manifest as chorea or dystonia.

15. (PREVIOUSLY PRESENTED) The method of claim 14, wherein the compound is topiramate.

16-18. (CANCELLED)

19. (PREVIOUSLY PRESENTED) The method of claim 14 or 27, wherein the dyskinesia is associated with dopamine replacement therapy.

20-24. (CANCELLED).

25. (PREVIOUSLY PRESENTED) The method of claim 14 or 27, wherein the dyskinesia arises as a side-effect of the treatment of parkinsonism with a therapeutic agent.

26. (PREVIOUSLY PRESENTED) The method of claim 25, wherein the therapeutic agent is selected from the group consisting of ropinirole, pramipexole, cabergoline, bromocriptine, lisuride, pergolide, L-DOPA and apomorphine.

27. (PREVIOUSLY PRESENTED) The method of claim 14, wherein the dyskinesia arises as a side-effect of a therapeutic agent.